Anti Cd 20 Ocrevus denied as non-formulary by Cigna?

Cigna's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Issues Non-Formulary Denials for Ocrelizumab

Cigna structures its drug formularies in tiers, and ocrelizumab (Ocrevus) may be placed on a non-preferred specialty tier or excluded from a specific plan's formulary, requiring a formulary exception before coverage will be extended. A non-formulary denial does not mean Cigna considers ocrelizumab medically wrong for MS — it means the plan will not cover it at standard benefit levels unless the patient or prescriber demonstrates that the formulary alternatives are medically inappropriate for this individual. That is precisely the argument a formulary exception appeal must make.

## Why This Denial Is Appealable

Non-formulary denials are adverse benefit determinations subject to your full appeal rights under ACA §2719 and ERISA §503. You have the right to an internal appeal and, if upheld, independent external review by a certified IRO. The external-review window is generally around four months from the adverse determination; confirm your exact deadline in your plan documents. Expedited review is available when delay poses a serious health risk. Cigna is also required to maintain a formulary-exception process; asking specifically for that pathway — in addition to or instead of a standard appeal — may produce a faster resolution.

## Your Appeal Timeline

1. Request the denial letter, Cigna's formulary for your plan, and the formulary-exception criteria — all are available on request. 2. Identify the formulary alternatives Cigna would prefer and assess whether any are clinically appropriate for this patient. 3. File a formulary exception request and/or internal appeal — document why each preferred alternative is inadequate. 4. Escalate to external review if the internal process does not result in approval.

## Documentation to Gather

• Formulary alternative trial and failure history: for each drug Cigna lists as a preferred alternative, provide chart records showing it was tried (with dates), the clinical response, and the reason it was discontinued or deemed inadequate.
• Contraindication or intolerance documentation: if the patient cannot safely try a preferred alternative, provide the chart notes, lab results, or specialist letters that document that conclusion — grounded in this patient's chart, not general population data.
• Prescriber exception letter: the neurologist should address each Cigna-preferred alternative by name, explain specifically why it is not appropriate for this patient's disease course and clinical situation, and state why ocrelizumab is the medically necessary option.
• Diagnosis and disease-activity records: current neurology notes, MRI reports, and functional assessments confirming ongoing clinical need.
• FDA prescribing label: confirm that the patient's MS subtype is an approved indication for ocrelizumab and attach the label as a reference document.
• Applicable guideline reference: a citation to the relevant neurology guideline organization supporting ocrelizumab use when alternatives are exhausted or contraindicated.

## Criteria-Mapping Structure

Obtain Cigna's formulary-exception criteria and map each requirement to the chart evidence:

| Exception Requirement | Chart Evidence | Source & Date | |---|---|---| | Trial of formulary alternative(s) | Treatment records with outcomes | [Date range] | | Reason alternative is inadequate | Prescriber letter / chart notes | [Date] | | Medical necessity of ocrelizumab | Current neurology assessment | [Date] | | Diagnosis confirmation | Neurology note, MRI report | [Date] |

Presenting this table as the opening exhibit in the exception request gives the Cigna reviewer a direct, unambiguous path to approval — reducing the risk that the request is denied for incomplete documentation a second time.